INT180588

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.52
First Reported 2004
Last Reported 2007
Negated 1
Speculated 0
Reported most in Body
Documents 13
Total Number 14
Disease Relevance 8.37
Pain Relevance 1.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (HEYL) protein binding transcription factor activity (HEYL) DNA binding (HEYL)
transcription factor binding (HEYL) cytoplasm (HEYL)
Anatomy Link Frequency
cartilage 3
uterus 2
HEYL (Homo sapiens)
Pain Link Frequency Relevance Heat
transdermal 2 99.98 Very High Very High Very High
rheumatoid arthritis 315 99.36 Very High Very High Very High
endometriosis 2 95.28 Very High Very High Very High
Inflammation 36 76.64 Quite High
corticosteroid 18 75.20 Quite High
cva 53 74.88 Quite High
Osteoarthritis 13 74.36 Quite High
metalloproteinase 18 71.76 Quite High
methotrexate 18 66.04 Quite High
cytokine 9 52.00 Quite High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 315 99.36 Very High Very High Very High
Obesity 123 98.80 Very High Very High Very High
Thyroid Disease 4 96.00 Very High Very High Very High
Endometriosis (extended) 57 95.28 Very High Very High Very High
Diabetes Mellitus 6 95.00 High High
Myocardial Infarction 24 94.24 High High
Weight Loss 4 92.36 High High
Heart Disease 4 91.68 High High
Reprotox - General 1 80 89.84 High High
Lobular Carcinoma 3 89.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In our study, we found that HRT, which may be used instead of BRS, remains normal in obese subjects.
Gene_expression (used) of HRT associated with obesity
1) Confidence 0.52 Published 2007 Journal Journal of Korean Medical Science Section Body Doc Link PMC2693810 Disease Relevance 1.45 Pain Relevance 0
HRT is highly correlated with spontaneous BRS, and it may be used instead of BRS (24).
Gene_expression (used) of HRT
2) Confidence 0.52 Published 2007 Journal Journal of Korean Medical Science Section Body Doc Link PMC2693810 Disease Relevance 1.36 Pain Relevance 0
The exclusion criteria for randomisation were:

• For the placebo controlled components: oral or transdermal HRT use in the last six months, ever use of HRT implant in women with a uterus, HRT implant inserted in last eight months in women with a hysterectomy. • History of endometriosis (hysterectomised or non-hysterectomised woman) or endometrial hyperplasia in a woman with a uterus. • History of invasive breast cancer, lobular carcinoma in-situ (LCIS), ductal carcinoma in-situ (DCIS), Paget's disease of the nipple or atypical hyperplasia of the breast. • Known BRCA1 or BRCA2 mutation carrier. • History of melanoma. • Invasive cancer at any other site apart from basal and squamous cell skin cancer within the last 10 years. • History of meningioma. • Myocardial infarction, cerebrovascular accident, sub-arachnoid haemorrhage or transient ischaemic attack within the last six months. • History of currently active liver disease or chronic liver disease but excluding Hepatitis A unless currently active. • Evidence of severe current renal impairment. • History of gall bladder disease in a woman who had not had a cholecystectomy or of gallstones following a cholecystectomy. • History of deep vein thrombosis, pulmonary embolism or retinal vein occlusion. • Positive thrombophilia screen (Factor V Leiden or prothrombin mutations, Protein C, Protein S or anti-thrombin III deficiencies, APC resistance, dysfibrinogenaemia or antiphospholipid antibodies). • Otosclerosis. • Porphyria. • History of hepatitis B, hepatitis C or HIV (not an exclusion in New Zealand). • Currently pregnant. • Currently taking or has taken contraceptive drugs in the last 12 months. • Current triglyceride level (fasting) > 5.5 mmol/l. • Active participant in any other intervention trial likely to affect trial outcomes. • Taking tamoxifen, toremifene, raloxifene or any other selective oestrogen receptor modulator (SERM). • Other conditions/circumstances where the general practitioner judged that it would not be possible to obtain fully informed consent and/or successfully complete trial procedures.


Gene_expression (use) of HRT in uterus associated with porphyria, endometriosis (extended), cv general 4 under development, skin cancer, hyperplasia, liver disease, endometriosis, conductive hearing loss, hepatitis, brain tumor, lobular carcinoma, thrombophilia, gallbladder disease, gallstones, hepatitis a virus infection, disease, retinal vein occlusion, thrombosis, pulmonary embolism, ductal carcinoma, transdermal, cancer, basal and squamous cell skin cancer, acquired immune deficiency syndrome or hiv infection, noninfiltrating intraductal carcinoma, cva, reprotox - general 1 and myocardial infarction
3) Confidence 0.09 Published 2007 Journal BMC Womens Health Section Body Doc Link PMC1828722 Disease Relevance 1.88 Pain Relevance 0.20
The exclusion criteria for randomisation were:

• For the placebo controlled components: oral or transdermal HRT use in the last six months, ever use of HRT implant in women with a uterus, HRT implant inserted in last eight months in women with a hysterectomy. • History of endometriosis (hysterectomised or non-hysterectomised woman) or endometrial hyperplasia in a woman with a uterus. • History of invasive breast cancer, lobular carcinoma in-situ (LCIS), ductal carcinoma in-situ (DCIS), Paget's disease of the nipple or atypical hyperplasia of the breast. • Known BRCA1 or BRCA2 mutation carrier. • History of melanoma. • Invasive cancer at any other site apart from basal and squamous cell skin cancer within the last 10 years. • History of meningioma. • Myocardial infarction, cerebrovascular accident, sub-arachnoid haemorrhage or transient ischaemic attack within the last six months. • History of currently active liver disease or chronic liver disease but excluding Hepatitis A unless currently active. • Evidence of severe current renal impairment. • History of gall bladder disease in a woman who had not had a cholecystectomy or of gallstones following a cholecystectomy. • History of deep vein thrombosis, pulmonary embolism or retinal vein occlusion. • Positive thrombophilia screen (Factor V Leiden or prothrombin mutations, Protein C, Protein S or anti-thrombin III deficiencies, APC resistance, dysfibrinogenaemia or antiphospholipid antibodies). • Otosclerosis. • Porphyria. • History of hepatitis B, hepatitis C or HIV (not an exclusion in New Zealand). • Currently pregnant. • Currently taking or has taken contraceptive drugs in the last 12 months. • Current triglyceride level (fasting) > 5.5 mmol/l. • Active participant in any other intervention trial likely to affect trial outcomes. • Taking tamoxifen, toremifene, raloxifene or any other selective oestrogen receptor modulator (SERM). • Other conditions/circumstances where the general practitioner judged that it would not be possible to obtain fully informed consent and/or successfully complete trial procedures.


Gene_expression (use) of HRT in uterus associated with porphyria, endometriosis (extended), cv general 4 under development, skin cancer, hyperplasia, liver disease, endometriosis, conductive hearing loss, hepatitis, brain tumor, lobular carcinoma, thrombophilia, gallbladder disease, gallstones, hepatitis a virus infection, disease, retinal vein occlusion, thrombosis, pulmonary embolism, ductal carcinoma, transdermal, cancer, basal and squamous cell skin cancer, acquired immune deficiency syndrome or hiv infection, noninfiltrating intraductal carcinoma, cva, reprotox - general 1 and myocardial infarction
4) Confidence 0.09 Published 2007 Journal BMC Womens Health Section Body Doc Link PMC1828722 Disease Relevance 1.84 Pain Relevance 0.20
We found that HRT reduced markers of both bone and cartilage metabolism and that the decrease in markers of bone turnover was associated with BMD gain.
Gene_expression (reduced) of HRT in cartilage
5) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.62 Pain Relevance 0.21
We found that CTX-I had decreased significantly in the HRT group, by 62% and 53% at 1 and 2 years, respectively.
Gene_expression (group) of HRT
6) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.35 Pain Relevance 0.13
The HRT group presented a marked decrease in serum levels of COMP, both between the HRT and control group (P = 0.003) and within the HRT group (P = 0.003).
Gene_expression (group) of HRT
7) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0 Pain Relevance 0
The impact of HRT on biochemical markers of bone and cartilage turnover
Gene_expression (impact) of HRT in cartilage
8) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0 Pain Relevance 0.13
HRT caused a pronounced decrease in the collagen type I degradation marker, CTX-I, both when the HRT and control groups were compared (P < 0.001) and within the HRT group (P < 0.001) (Fig. 1a).
Gene_expression (compared) of HRT
9) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0 Pain Relevance 0.03
In the present investigation, CTX-II in the urine decreased significantly within the HRT group, a finding that implies that HRT has a protective effect on cartilage.
Gene_expression (group) of HRT in cartilage
10) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.30 Pain Relevance 0.15
After the second year, a significant decrease was found within the HRT group (P = 0.021) in comparison with baseline values.
Gene_expression (group) of HRT
11) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0 Pain Relevance 0
HRT caused a pronounced decrease in the collagen type I degradation marker, CTX-I, both when the HRT and control groups were compared (P < 0.001) and within the HRT group (P < 0.001) (Fig. 1a).
Gene_expression (compared) of HRT
12) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0 Pain Relevance 0.03
In our study, HRT exerted a suppressive effect, apparent as an increase of BSP in the control group but not in the HRT group.
Neg (not) Gene_expression (group) of HRT
13) Confidence 0.04 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC546286 Disease Relevance 0.17 Pain Relevance 0.11
We therefore do not believe that HRT status had any significant impact on our results, namely a lack of correlation between mammographic density and Ki-67 expression.
Gene_expression (status) of HRT
14) Confidence 0.04 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC1929099 Disease Relevance 0.39 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox